Lantheus控股 LNTH 深 沪
已收盘 02-06 16:00:00 美东时间
64.89
+0.030
+0.05%
华盛通- 最 高66.05
- 今 开65.51
- 成交量 84.66万股
- 最 低 63.84
- 昨 收 64.86
- 总市值 43.03亿
- 52周最高 111.29
- 市盈率 静 14.88
- 换手率 1.28%
- 52周最低 47.25
- 委 比 -91.17%
- 总股本 6631.18万
- 历史最高 126.8899
- 量 比 1.19
- 振 幅 3.41%
- 历史最低 1.76
- 每 手 1
- 风险率 16.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
Lantheus Holdings announced the completion of the sale of its SPECT business to SHINE Technologies, including its diagnostic agents and manufacturing assets. The transaction allows Lantheus to focus on its PET radiodiagnostics and microbubble portfolio. SHINE, a leader in fusion technology, will integrate these products into its medical isotope production. The SPECT-related products, such as TechneLite, Xenon Xe-133 Gas, NEUROLITE, and Cardiolite...
01-02 13:00
Lifeward Appoints Bob Marshall as Chairman of the Board
Lifeward Ltd. announced that Bob Marshall has been appointed as Chairman of the Board, effective January 1, 2026, replacing Joseph Turk, who is transitioning to a new role at Fresenius Medical Care. CEO Mark Grant expressed gratitude for Turk's leadership and welcomed Marshall, highlighting his expertise and strategic insights. Marshall, currently CFO and Treasurer of Lantheus Holdings, has extensive experience in healthcare and finance. Lifeward...
2025-12-19 21:05
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
Truist Securities Upgrades Lantheus Holdings to Buy, Raises Price Target to $80
Truist Securities analyst Richard Newitter upgrades Lantheus Holdings (NASDAQ:LNTH) from Hold to Buy and raises the price target from $61 to $80.
2025-12-12 22:44
Lantheus to Present Florbetaben F 18 Data at CTAD 2025
Lantheus Holdings, Inc. announced the presentation of new florbetaben F18 data at the CTAD 2025 conference in San Diego. The poster presentation, titled "Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab," will be displayed on December 3. Neuraceq (florbetaben F 18 injection) is used for PET imaging to estimate amyloid beta plaque density in adults with cognitive impairment. Important saf...
2025-11-24 13:30
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
2025-11-11 10:49
Lantheus Holdings Narrows FY2025 Adj EPS Guidance from $5.50-$5.70 to $5.50-$5.65 vs $5.63 Est; Raises FY2025 Sales Guidance from $1.475B-$1.510B to $1.490B-$1.510B vs $1.483B Est
Lantheus Holdings (NASDAQ:LNTH) narrows FY2025 Adj EPS guidance from $5.50-$5.70 to $5.50-$5.65 vs $5.63 analyst estimate. Raises FY2025 sales outlook from $1.475 billion-$1.510 billion to $1.490 billion-$1.510 billion
2025-11-06 20:19
Lantheus CEO Brian Markison To Retire, Effective Dec. 31; Mary Anne Heino Appointed Executive Chairperson, Interim CEO, Effective Nov. 7; President Paul Blanchfield Departing
Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today
2025-11-06 20:19
